HOME > TOP STORIES
TOP STORIES
-
REGULATORY DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
-
BUSINESS FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
-
BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
-
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
-
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
-
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
-
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
-
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
-
COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
-
BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
-
BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
-
ORGANIZATION FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
-
BUSINESS AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
-
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
-
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
-
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
-
REGULATORY Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
-
REGULATORY Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up
January 28, 2026
-
REGULATORY Former LDP Lawmakers Outline Drug Policy Priorities in Comeback Bids
January 28, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
